258 related articles for article (PubMed ID: 31068179)
1. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
2. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
[TBL] [Abstract][Full Text] [Related]
3. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Carvalho S; Troost EG; Bons J; Menheere P; Lambin P; Oberije C
Radiother Oncol; 2016 Jun; 119(3):487-94. PubMed ID: 27139126
[TBL] [Abstract][Full Text] [Related]
9. The relationship between serum VEGF concentration and prognosis of lung cancer.
Park SH; Lee SS
Korean J Intern Med; 2003 Dec; 18(4):207-11. PubMed ID: 14717227
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic Performance of Serum Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor 2, and Osteopontin for Gastrointestinal Cancers.
Jiang L; Hochwald S; Deng S; Chen Y; Tan C; Zhong Q; Huang H
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775874
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
Rades D; Setter C; Dunst J; Dahl O; Schild SE; Noack F
Strahlenther Onkol; 2010 Jun; 186(6):307-14. PubMed ID: 20437013
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
14. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
[TBL] [Abstract][Full Text] [Related]
15. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Shimanuki Y; Takahashi K; Cui R; Hori S; Takahashi F; Miyamoto H; Fukurchi Y
Lung; 2005; 183(1):29-42. PubMed ID: 15793665
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.
Kerenidi T; Kazakou AP; Lada M; Tsilioni I; Daniil Z; Gourgoulianis KI
Cancer Invest; 2016 Sep; 34(8):385-92. PubMed ID: 27624849
[TBL] [Abstract][Full Text] [Related]
17. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum osteopontin levels in small cell lung cancer.
Xu C; Yuan Q; Wang W; Chi C; Zhang Q; Li L; Yang R; Wang Y
BMC Pulm Med; 2020 Sep; 20(1):235. PubMed ID: 32873264
[TBL] [Abstract][Full Text] [Related]
19. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
Isa S; Kawaguchi T; Teramukai S; Minato K; Ohsaki Y; Shibata K; Yonei T; Hayashibara K; Fukushima M; Kawahara M; Furuse K; Mack PC
J Thorac Oncol; 2009 Sep; 4(9):1104-10. PubMed ID: 19620934
[TBL] [Abstract][Full Text] [Related]
20. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
